Assenagon Asset Management S.A. Sells 98,325 Shares of Evolus, Inc. $EOLS

Key Points

• Assenagon Asset Management S.A. has reduced its stake in Evolus, Inc. by 13.8%, selling 98,325 shares, and now holds approximately 0.95% of the company's total shares.
• Institutional investors own 90.69% of Evolus, with significant increases in holdings from firms like Jane Street Group LLC and UBS Asset Management.
• Analyst ratings for Evolus feature a consensus of "Moderate Buy" and varying price targets, with the highest set at $22.00 and the lowest at $18.00.

Assenagon Asset Management S.A. trimmed its position in Evolus, Inc. (NASDAQ:EOLS - Free Report) by 13.8% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 612,388 shares of the company's stock after selling 98,325 shares during the quarter. Assenagon Asset Management S.A. owned about 0.95% of Evolus worth $5,640,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of EOLS. Rhumbline Advisers raised its holdings in Evolus by 4.1% in the 1st quarter. Rhumbline Advisers now owns 83,436 shares of the company's stock worth $1,004,000 after acquiring an additional 3,287 shares during the period. Jane Street Group LLC increased its stake in shares of Evolus by 484.8% in the first quarter. Jane Street Group LLC now owns 69,947 shares of the company's stock worth $841,000 after purchasing an additional 57,987 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Evolus by 36.1% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 156,565 shares of the company's stock worth $1,883,000 after purchasing an additional 41,513 shares during the last quarter. Zimmer Partners LP boosted its stake in Evolus by 21.2% during the 1st quarter. Zimmer Partners LP now owns 505,000 shares of the company's stock valued at $6,075,000 after purchasing an additional 88,500 shares during the period. Finally, Jones Financial Companies Lllp acquired a new stake in Evolus in the 1st quarter valued at approximately $158,000. 90.69% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Evolus

In other Evolus news, CMO Tomoko Yamagishi-Dressler sold 5,722 shares of the business's stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $7.51, for a total transaction of $42,972.22. Following the completion of the transaction, the chief marketing officer owned 89,949 shares of the company's stock, valued at approximately $675,516.99. The trade was a 5.98% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Brady Stewart purchased 30,000 shares of Evolus stock in a transaction dated Friday, August 15th. The shares were purchased at an average price of $6.82 per share, for a total transaction of $204,600.00. Following the completion of the acquisition, the director owned 88,629 shares of the company's stock, valued at approximately $604,449.78. The trade was a 51.17% increase in their position. The disclosure for this purchase can be found here. 5.90% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

EOLS has been the subject of several research reports. BTIG Research reissued a "buy" rating and issued a $18.00 price objective on shares of Evolus in a research report on Monday, September 8th. Wall Street Zen cut shares of Evolus from a "hold" rating to a "sell" rating in a research note on Saturday, August 9th. HC Wainwright decreased their price target on shares of Evolus from $27.00 to $20.00 and set a "buy" rating on the stock in a research report on Wednesday, August 6th. Finally, Needham & Company LLC restated a "hold" rating and set a $22.00 price objective on shares of Evolus in a report on Wednesday, August 6th. Three research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat.com, Evolus currently has a consensus rating of "Moderate Buy" and an average target price of $21.25.

Evolus Price Performance

NASDAQ EOLS opened at $6.09 on Thursday. The firm's 50 day moving average is $7.59 and its 200-day moving average is $9.53. Evolus, Inc. has a 12-month low of $5.71 and a 12-month high of $17.82. The company has a quick ratio of 1.86, a current ratio of 2.27 and a debt-to-equity ratio of 22.00. The company has a market capitalization of $393.90 million, a PE ratio of -6.21 and a beta of 1.07.

Evolus Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.